Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT8GVU)

• Drug Name: 177Lu-DOTATATE Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 76966897
  CAS Number: CAS 437608-50-9
  TTD Drug ID: DMT8GVU

Molecule-Related Drug Atlas

Drug(s) Targeting Somatostatin receptor (SSTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
177Lu-DOTA-octreotate	DMP5L8S	Melanoma	2C30	Phase 3	[2]
177-Lu-oxodotreotide	DMMZS2T	Neuroendocrine cancer	2B72.1	Phase 3	[4]
Somatoprim	DMTVS3A	Acromegaly	5A60.0	Phase 2	[5]
Edotreotide	DMQ08AJ	Acromegaly	5A60.0	Phase 2	[6]
FK-962	DMV0MZ3	Alzheimer disease	8A20	Phase 2	[7]
177Lu-labelled DOTA-JR11	DMVZ9XL	Neuroendocrine cancer	2B72.1	Phase 1/2	[8]
212Pb-labelled DOTAMTATE	DMN9MPX	Neuroendocrine cancer	2B72.1	Phase 1	[9]
AlphaMedix	DMBVM1Q	Neuroendocrine cancer	2B72.1	Phase 1	[10]
FK-960	DMPD8O2	Cognitive impairment	6D71	Discontinued in Phase 2	[7]
SEGLITIDE	DMXZVPH	Pain	MG30-MG3Z	Discontinued in Phase 2	[11]

Drug(s) Targeting Somatostatin receptor type 4 (SSTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[12]
LY3556050	DMTW2XB	Chronic low-back pain	MG30	Phase 2	[13]
CNTX-0290	DMJPEVA	Chronic pain	MG30	Phase 1	[14]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[15]
SOMATOSTATIN	DMIOFQE	Acromegaly	5A60.0	Investigative	[16]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[17]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[12]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[18]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[19]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor (SSTR)	TTOMNR9	NOUNIPROTAC	Modulator	[2]
Somatostatin receptor type 4 (SSTR4)	TTAE1BR	SSR4_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT01860742) Randomized Phase III of PRRT Versus Interferon. U.S. National Institutes of Health.
• [2] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
• [3] New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
• [4] Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
• [5] DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
• [8] Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
• [9] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [10] Clinical pipeline report, company report or official report of Orano Med.
• [11] Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.
• [12] Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
• [13] ClinicalTrials.gov (NCT04874636) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
• [16] Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
• [17] Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
• [18] Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358).